Controlled delivery of antigens and adjuvants in vaccine development (Q41264942)

28 September 2017

1 reference

title

Controlled delivery of antigens and adjuvants in vaccine development (English)

1 reference

28 September 2017

2

1 reference

28 September 2017

Zhao Z

1

1 reference

PubMed ID

8961136

28 September 2017

language of work or name

English

0 references

publication date

1 December 1996

1 reference

Journal of Pharmaceutical Sciences

28 September 2017

1 reference

28 September 2017

85

1 reference

28 September 2017

12

1 reference

28 September 2017

1261-1270

1 reference

Genetically engineered tumor vaccines

28 September 2017

1 reference

7 January 2021

New strategies for enhancing the immunogenicity of tumors

1 reference

7 January 2021

The use of gene-modified tumor-infiltrating lymphocytes for cancer therapy

1 reference

7 January 2021

The development of gene therapy for the treatment of cancer

1 reference

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

7 January 2021

The antitumor immune response as a problem of self-nonself discrimination: implications for immunotherapy

1 reference

7 January 2021

In vivo cytokine gene transfer by gene gun reduces tumor growth in mice

1 reference

7 January 2021

Targeting and controlled release of antigens for the effective induction of secretory antibody responses

1 reference

7 January 2021

Strategies for exploiting the immune system in the design of vaccines

1 reference

7 January 2021

Future approaches to vaccine development: single-dose vaccines using controlled-release delivery systems

1 reference

7 January 2021

Biodegradable microspheres as controlled-release tetanus toxoid delivery systems.

1 reference

7 January 2021

Determinants of release rate of tetanus vaccine from polyester microspheres.

1 reference

7 January 2021

A single-step immunization by sustained antigen release

1 reference

7 January 2021

Enhancement of rotavirus immunogenicity by microencapsulation

1 reference

7 January 2021

Comparative efficacy of biodegradable liposomes and microspheres as carriers for delivery of Vibrio cholerae antigens in the intestine

1 reference

7 January 2021

Enhancement of protective immune responses to Venezuelan equine encephalitis (VEE) virus with microencapsulated vaccine

1 reference

7 January 2021

Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles

1 reference

7 January 2021

Influence of the particle size on the adjuvant effect of particulate polymeric adjuvants

1 reference

7 January 2021

Particle size studies for subcutaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation

1 reference

7 January 2021

Protection against vaginal SIV transmission with microencapsulated vaccine

1 reference

7 January 2021

Biodegradable microspheres as a vaccine delivery system

1 reference

7 January 2021

Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

1 reference

7 January 2021

A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide

1 reference

7 January 2021

Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide).

1 reference

7 January 2021

Potentiality of gelatin microsphere as immunological adjuvant

1 reference

7 January 2021

Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers

1 reference

7 January 2021

Influence of drug loading level on drug release and dynamic swelling of crosslinked gelatin microspheres

1 reference

7 January 2021

In vivo effects of recombinant interferon alpha A/D incorporated in gelatin microspheres on murine tumor cell growth.

1 reference

7 January 2021

Synthesis of gelatin microspheres containing interferon

1 reference

7 January 2021

Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of desmuramyl peptidolipid analogs.

1 reference

7 January 2021

Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres

1 reference

7 January 2021

Liposomes containing lipid A as a potent non-toxic adjuvant

1 reference

7 January 2021

Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants

1 reference

7 January 2021

Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes

1 reference

7 January 2021

Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study

1 reference

7 January 2021

Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A

1 reference

7 January 2021

Liposomes as immunological adjuvants

1 reference

7 January 2021

Liposomes as carriers of antigens and adjuvants

1 reference

7 January 2021

Immunological adjuvants: a role for liposomes

1 reference

7 January 2021

Hepatitis B surface antigen-containing liposomes enhance humoral and cell-mediated immunity to the antigen

1 reference

7 January 2021

Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs

1 reference

7 January 2021

Liposomal encapsulation augments delayed hypersensitivity reactions to tuberculin proteins

1 reference

7 January 2021

Liposome-mediated delivery stimulates a class I-restricted cytotoxic T cell response to soluble antigen

1 reference

7 January 2021

Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro

1 reference

7 January 2021

Importance of physical association between antigen and liposomes in liposomes adjuvanticity

1 reference

7 January 2021

Association of an albumin antigen with phosphatidylcholine liposomes alters the nature of immunoglobulins produced during the immune response against the antigen

1 reference

7 January 2021

Development of a new type of influenza subunit vaccine made by muramyldipeptide-liposome: enhancement of humoral and cellular immune responses

1 reference

7 January 2021

Vaccination of Experimental Monkeys Against Plasmodium falciparum : A Possible Safe Adjuvant

1 reference

7 January 2021

Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid)

1 reference

7 January 2021

The immunodominant peptide from listeriolysin in Quil A liposomes vaccinates CD8+ cytolytic T cells and confers protection to infection

1 reference

7 January 2021

Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells

1 reference

7 January 2021

Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy

1 reference

7 January 2021

Liposomes containing lipid A: a potent nontoxic adjuvant for a human malaria sporozoite vaccine

1 reference

7 January 2021

Adjuvants--a balance between toxicity and adjuvanticity

1 reference

7 January 2021

Delivery of interleukin 2 for immunotherapy

1 reference

7 January 2021

Antitumor effect of interleukin-2 entrapped in liposomes on murine renal cell carcinoma

1 reference

7 January 2021

Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-gamma

1 reference

7 January 2021

Inhibition of growth of rat hepatoma by local injection of liposomes containing recombinant interleukin-2. Antitumor effect of IL-2 liposome

1 reference

7 January 2021

Immunotherapy of a mouse mammary carcinoma by sustained peritumor release of IL-2

1 reference

7 January 2021

Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines

1 reference

7 January 2021

Cytokine-containing liposomes as adjuvants for HIV subunit vaccines

1 reference

7 January 2021

The non-specific enhancement of allergy. II. Precipitation of anaphylactic in vitro response capacity and serum IgE and IgG2a antibody synthesis in primed but non-responding rats by injection of alum

1 reference

7 January 2021

Tumor escape from immune response by variation in HLA expression and other mechanisms

1 reference

7 January 2021

[Color-coded duplex sonography in the differential diagnosis of cervical lymph node enlargements]

1 reference

7 January 2021

The mesentery as a laminated vascular bed for hepatocyte transplantation

1 reference

7 January 2021

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

1 reference

7 January 2021

Murine interleukin-4 displays potent anti-tumor activity in vivo

1 reference

7 January 2021

Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules

1 reference

7 January 2021

Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity

1 reference

7 January 2021

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

1 reference

7 January 2021

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

1 reference

7 January 2021

MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice.

1 reference

7 January 2021

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

1 reference

7 January 2021

Glutaraldehyde cross-linked bovine casein microspheres as a matrix for the controlled release of theophylline: in-vitro studies

1 reference

7 January 2021

Metabolic dependence of red cell deformability

1 reference

7 January 2021

In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy.

1 reference

7 January 2021

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

7 January 2021

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

1 reference

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

7 January 2021

Unconventional cytotoxic T lymphocyte recognition of synthetic peptides corresponding to residues 1—23 of Ras protein

1 reference

7 January 2021

Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein

1 reference

7 January 2021

Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus

1 reference

7 January 2021

Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein

1 reference

7 January 2021

Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells

1 reference

7 January 2021

An eosinophil-dependent mechanism for the antitumor effect of interleukin-4

1 reference

7 January 2021

Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity

1 reference

7 January 2021

A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability

1 reference

7 January 2021

Augmentation of antitumor effect on syngeneic murine solid tumors by an interleukin 2 slow delivery system, the IL-2 mini-pellet

1 reference

7 January 2021

Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection

1 reference

7 January 2021

Modulation of systemic cytokine levels by implantation of alginate encapsulated cells

1 reference

7 January 2021

Antitumor effects of liposomal IL1 alpha and TNF alpha against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice.

1 reference

7 January 2021

Effect of immunomodulators on specific tumor immunity induced by liposome-encapsulated tumor-associated antigens

1 reference

7 January 2021

Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity

1 reference

7 January 2021

Protection against Mycoplasma pulmonis infection by genetic vaccination

1 reference

7 January 2021

Facilitated DNA inoculation induces anti-HIV-1 immunity in vivo

1 reference

7 January 2021

Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen

1 reference

7 January 2021

Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA

1 reference

7 January 2021

A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine

1 reference

7 January 2021

Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization

1 reference

7 January 2021

Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines

1 reference

7 January 2021

Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB).

1 reference

7 January 2021

Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors.

1 reference

7 January 2021

Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine.

1 reference

7 January 2021

Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.

1 reference

7 January 2021

Immune responses to plasmid DNA encoding the hepatitis C virus core protein

1 reference

7 January 2021

Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein

1 reference

7 January 2021

Biotechnological and gene therapeutic strategies in cancer treatment

1 reference

7 January 2021

Macrophage colony-stimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma

1 reference

7 January 2021

DNA vaccination against persistent viral infection.

1 reference

7 January 2021

Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins

1 reference

7 January 2021

Generation of allo-reactive cytotoxic T lymphocytes by particle bombardment-mediated gene transfer

1 reference

7 January 2021

Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes

1 reference

7 January 2021

Direct gene transfer for the understanding and treatment of human disease

1 reference

7 January 2021

Genes coding for tumor antigens recognized by human cytolytic T lymphocytes

1 reference

7 January 2021

Cationic liposomes for direct gene transfer in therapy of cancer and other diseases.

1 reference

7 January 2021

Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans

1 reference

7 January 2021

Immunotherapy of malignancy by in vivo gene transfer into tumors

1 reference

7 January 2021

DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations

1 reference

7 January 2021

Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus

1 reference

7 January 2021

Identifiers

DOI

10.1021/JS9602812

1 reference

28 September 2017

1 reference

PubMed ID

8961136